ArticleInfection and drug resistance2022
Risk Factors for Mortality and Outcomes in Hematological Malignancy Patients with Carbapenem-Resistant
Article in Infection and drug resistance, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Female Sex and Mortality in Patients With Gram-Negative Bacteremia: A Systematic Review and Meta-Analysis.JAMA network open · 2025Pooled it
- Pooled it
- Pooled it
- Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-ResistantJournal of Korean medical science · 2026Article
- NDM-ProducingJournal of clinical medicine · 2026Article
- Determinants of Carbapenem-ResistantAntibiotics (Basel, Switzerland) · 2026Article
- Clinical and microbiological characteristics of polymicrobial bloodstream infections in hematologic malignancy patients: a cross-sectional study.BMC infectious diseases · 2026Article
- Impact of Oxacillinase-48 (OXA-48) and New Delhi Metallo-β-Lactamase (NDM) Co-existence on Mortality in Critically Ill Patients withJournal of clinical practice and research · 2026Article
- Clinical Characteristics, Risk Factors and Prognosis of Carbapenem-ResistantInfection and drug resistance · 2025Article
- Retrospective Case-Control Study of Risk Factors for Carbapenem-ResistantPathogens (Basel, Switzerland) · 2024Article
- Resistance Genes and Mortality in Carbapenem-resistantBalkan medical journal · 2024Observational
- Relationship between virulence and carbapenem resistance phenotype ofZhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2024Article
- Retrospective analysis of molecular characteristics, risk factors, and outcomes in carbapenem-resistant Klebsiella pneumoniae bloodstream infections.BMC microbiology · 2024Observational
- Ceftazidime-Avibactam in the Treatment of Patients with Bacteremia or Nosocomial Pneumonia: A Systematic Review and Meta-analysis.Infectious diseases and therapy · 2024Article
- Comparison of bacteremic pneumonia caused bySaudi medical journal · 2024Article
- Clinical Outcomes and Risk Factors for Death in Critically Ill Patients with Carbapenem-ResistantInfection and drug resistance · 2024Article
- Clinical Predictors of Bacteremia Outcome After Initial Empirical Antimicrobial Therapy in Patients with Hematological Malignancies: A Retrospective Analysis.Infection and drug resistance · 2024Article
- Epidemiology and outcomes of carbapenem-resistantFrontiers in microbiology · 2024Article
- Development of a Clinical Score to Stratify the Risk for Carbapenem-Resistant Enterobacterales Bacteremia in Patients with Cancer and Hematopoietic Stem Cell Transplantation.Antibiotics (Basel, Switzerland) · 2023Article
- Clinical Characteristics and Prognosis of Bloodstream Infection with Carbapenem-ResistantInfection and drug resistance · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: This study aimed to identify risk factors for mortality and outcomes in hematological malignancy (HM) patients with bloodstream infection (BSI) caused by carbapenem-resistant Methods: A retrospective study was conducted at a tertiary teaching hospital in Henan Province, China, between January 2018 and December 2021. All BSIs caused by CRKP in hospitalized HM patients were identified. Data on patient demographics, disease, laboratory tests, treatment regimens, outcomes of infection, and the antimicrobial susceptibility of each isolate were collected from medical records. Results: A total of 129 patients with CRKP BSI were included in the study, and the 28-day mortality rate was 80.6% (104/129). In Cox analysis an absolute neutrophil count < 500 at discharge (hazard ratio [HR] 6.386, 95% confidence interval [CI] 3.074-13.266, Conclusion: In HM patients CRKP BSI resulted in high mortality. Intensive care unit admission, higher Pitt bacteremia score, and absolute neutrophil count < 500 at discharge were independently associated with higher mortality. Early initiation of new agents such as ceftazidime-avibactam may improve outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.